170 filings
Page 3 of 9
8-K
dfd1oypq5yx
2 Apr 21
Other Events
5:00pm
8-K
dz3wfpt8 00ldabk
29 Mar 21
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
4:01pm
8-K
fut0 741p
29 Mar 21
Regulation FD Disclosure
9:18am
8-K
wkusguo2
5 Feb 21
Departure of Directors or Certain Officers
4:24pm
8-K
e7xfraj0y25iz8yet
29 Jan 21
Humanigen Completes Enrollment in Phase 3 Study of Lenzilumab in Hospitalized Patients with COVID-19
7:30am
8-K
86rhsh56bqs
22 Jan 21
Humanigen Announces the Addition of BARDA and Expansion of CRADA with the U.S. Government to Develop Lenzilumab for COVID-19
10:41am
8-K
5mdl c6zs8flv7
19 Jan 21
Other Events
5:24pm
8-K
xqn3e5557ra v7
14 Jan 21
Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19
4:30pm
8-K
3kb9 lyc2
11 Jan 21
Regulation FD Disclosure
6:07am
8-K
pik 7u77nqp4
7 Jan 21
Departure of Directors or Certain Officers
4:30pm
8-K
gcr33jck2nk0mjniyyzw
31 Dec 20
Other Events
4:37pm
8-K
tguwhr993yz17hjpjcnc
12 Nov 20
Results of Operations and Financial Condition
6:06am
8-K
px7uxa cjhg2c26
6 Nov 20
Humanigen Announces Cooperative Research and Development Agreement with the Department of Defense to Develop Lenzilumab for COVID-19
9:05am
8-K
nx0e poys6
4 Nov 20
Humanigen Executes Licensing Agreement for Lenzilumabâ„¢ in COVID-19 with KPM Tech/Telcon RF Pharmaceutical for South Korea and the Philippines
4:45pm
8-K
amd9j m0kruvs6
7 Oct 20
Departure of Directors or Certain Officers
4:15pm
8-K
64i87l8 0l1y1f
21 Sep 20
Other Events
8:26am
8-K
ent5so1e
11 Sep 20
Departure of Directors or Certain Officers
4:43pm
8-K
vptvk 0sroj
4 Sep 20
Other Events
4:36pm
8-K
nm07fyg6h4c0
10 Aug 20
Regulation FD Disclosure
9:08am
8-K
y7w8ogg40yd7ah9x78
3 Aug 20
Departure of Directors or Certain Officers
8:30am